Wire · opportunities
Nelkarmi wins FDA accelerated approval for ALK-positive lung cancer after alectinib or ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer after progression on alectinib or multiple prior ALK inhibitors and chemotherapy, based on tumor response rates from a Phase 1/2 trial. The approval provides an additional targeted treatment option for this patient subgroup, though ongoing confirmatory trials are required to verify long-term clinical benefit.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your drug targeting ALK-positive lung cancer gains US market access faster but faces pressure to confirm survival benefits. With neladalkib approved post-alectinib, your clinical strategy must emphasise durable response and brain metastases activity to compete.
◆ Coverage
1 source · 18 Nov 2026
◆ Related on Wire
◆ Topics